AMT 021

Drug Profile

AMT 021

Alternative Names: AAV5-AAT-PBGD; AAV5-PBGD gene therapy; AMT-020; AMT-021; rAAV2/5-PBGD

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Digna Biotech; University of Navarra
  • Developer uniQure
  • Class Gene therapies
  • Mechanism of Action Hydroxymethylbilane synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Acute intermittent porphyria

Most Recent Events

  • 28 Aug 2017 Protein Sciences Corporation has been acquired by Sanofi
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Acute-intermittent-porphyria in Spain (IV, Injection)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-intermittent-porphyria in Netherlands (IV, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top